Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3

Phase 2negativeNegative

AI Analysis

Summary

Acadia Pharmaceuticals reported a Phase 2 failure for an experimental drug in Alzheimer's disease psychosis, but plans to advance to Phase 3 with a modified approach based on observed signal.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Phase 2 study failed in Alzheimer's disease psychosis

Importance:6/10

Sentiment:

-0.40

Phase 2 failureAlzheimer's diseasepsychosisclinical trialdrug development

Related Companies

$ACAD

Read the original article

Published by Endpoints News on September 24, 2026 2:50 PM

Read Original